- Home
- NVT vs ROIV Comparison
NVT vs ROIV Comparison
Compare NVT & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVT | ROIV |
|---|---|---|
| Founded | 1903 | 2014 |
| Country | United Kingdom | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.7B | 20.7B |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NVT | ROIV |
|---|---|---|
| Price | $137.46 | $29.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 9 |
| Target Price | ★ $131.36 | $28.94 |
| AVG Volume (30 Days) | 1.8M | ★ 4.2M |
| Earning Date | 05-01-2026 | 05-28-2026 |
| Dividend Yield | ★ 0.62% | N/A |
| EPS Growth | ★ 118.78 | N/A |
| EPS | ★ 4.31 | N/A |
| Revenue | ★ $3,893,100,000.00 | $29,053,000.00 |
| Revenue This Year | $19.44 | N/A |
| Revenue Next Year | $12.41 | $744.61 |
| P/E Ratio | $31.47 | ★ N/A |
| Revenue Growth | ★ 29.51 | N/A |
| 52 Week Low | $52.06 | $10.58 |
| 52 Week High | $136.29 | $30.33 |
Technical Indicators
Market Signals| Indicator | NVT | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 65.88 | 57.91 |
| Support Level | $94.87 | $20.46 |
| Resistance Level | N/A | $30.33 |
| Average True Range (ATR) | 3.95 | 0.85 |
| MACD | 1.01 | 0.10 |
| Stochastic Oscillator | 89.15 | 73.60 |
Price Performance
Historical ComparisonAbout NVT nVent Electric plc
NVent is a leading global provider of electrical connection and protection solutions that touch a broad range of end markets, including infrastructure, industrial, commercial, and residential. NVent designs, manufactures, markets, installs, and services a portfolio of electrical enclosures and electrical fastening solutions. North America accounts for the majority of sales.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.